Skip to main content

Table 2 Baseline characteristics of patients who failed to achieved SVR12

From: Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B

Parameter

Non-responders

N = 3

Relapsers

N = 3

Discontinued due to adverse events

N = 9

P value

Age (years)

 Mean ± SD

56.33 ± 6.66

51.33 ± 8.13

60.44 ± 6.24

0.18

  (Min–Max)

(49–62)

(41–61)

(52–70)

Gender

 Male

1(33.3%)

2(66.7%)

6(66.7%)

0.57

 Female

2(66.7%)

1(33.3%)

3(33.3%)

Prior HCV treatment

 Naïve

2(66.7%)

3(100%)

7(77.8%)

0.57

 Experienced

1(33.3%)

0(0%)

2(22.2%)

Laboratory data

 Hemoglobin (gm/dl)

13.3 ± 2.3

12.73 ± 1.11

11.36 ± 1.32

0.14

 Male: (13.2–17.5 gm/dl)

    

 Female: (11.5–16 gm/dl)

    

WBCs × 103/ml (4–11 × 103/ml)

3.3 ± 0.36

5.7 ± 2.1

3.26 ± 1.12

0.035

Platelet count × 103/ml (150–450 × 103/ml)

58 (58–100)

84 (74–111)

111 (55–142)

0.33

PCR (IU/ml) × 103

4780 (216.218–4823)

1210 (393–1490)

429 (10.780–1603.390)

0.19

ALT/ULN (fold)

1.05 (0.78–4.12)

1.03 (0.8–1.24)

0.93 (0.48–2.85)

0.49

AST/ULN (fold)

1.62 (1.03–4.7)

1.85 (1.38–3.41)

1.73 (0.4–3.46)

0.91

Serum albumin (g/dl) (3.4–5.4 g/dl)

3 ± 0.26

2.53 ± 0.25

2.8 ± 0.24

0.10

Serum bilirubin (mg/dl) (0.3–1 mg/dl)

1.77 ± 0.6

2.3 ± 0.79

1.54 ± 1

0.48

I.N.R. (0.9–1.2)

1.42 ± 0.28

1.42 ± 0.14

1.3 ± 0.18

0.53

Serum creatinine (mg/dl)

 Male: (0.6–1.2 mg/dl)

0.6 ± 0.1

0.87 ± 0.4

1.17 ± 0.4

0.09

 Female: (0.8–1.4 mg/dl)

    

AFP (μg/l) (< 8 μg/l)

12 (6.5–83)

10.2 (9–20.7)

7.6 (2.64–25)

0.37

MELD score

 Median

12

14

13

 

  (Min–max)

(11–13)

(11–17)

(8–18)

0.62

 < 10

0(0%)

0(0%)

2(22.2%)

0.46

 ≥ 10

3(100%)

3(100%)

7(77.8%)

 

Ultrasonographic features

 Liver cirrhosis

3(100%)

3(100%)

9(100)

P = 1.0

 Splenomegaly

1(33.3%)

1(33.3%)

4(44.4%)

P = 0.9

 Ascites

1(33.3%)

1(33.3%)

9(100%)

P = 0.02

 Hemangioma

1(33.3%)

0(0%)

0(0%)

P = 0.12

 Ablated HCC

0(0%)

0(0%)

0(0%)

 

Child-Pugh score

 B7

3(100%)

1(33.3%)

2(22.2%)

0.19

 B8

0(0%)

1(33.3%)

5(55.6%)

 

 B9

0(0%)

1(33.3%)

2(22.2%)